C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q3 EPS of ($0.35), $0.03 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $15.36 million versus the consensus estimate of $5.9 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.